Скачать или смотреть Comparing atezolizumab & bevacizumab with STRIDE in advanced HCC

Federica Lo Prinzi, MD, Fondazione Policlinico Universitario Campus Bio- Medico, Rome, Italy, comments on a retrospective real-world analysis comparing atezolizumab plus bevacizumab with tremelimumab and durvalumab (STRIDE) as first-line therapy for advanced hepatocellular carcinoma (HCC). Using matched patient cohorts, the study found no significant difference in overall survival between the two treatment strategies, suggesting both regimens represent valid options in this setting. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.